INVO Fertility, Inc Stock Price, News & Analysis

INVO Fertility (Nasdaq: IVF) signed a definitive purchase agreement to acquire Family Beginnings, a fertility clinic serving Indiana and the Midwest, advancing a previously announced intent from Nov 27, 2025.

Key terms: purchase price $750,000 for non-clinical assets, $350,000 cash at closing (subject to $150,000 holdback), and $400,000 in Series D non-voting convertible preferred stock. Family Beginnings reported $1.2M revenue and $0.2M net income for the trailing 12 months ended Sept 30, 2025. Closing expected no later than Feb 27, 2026. Dr. James Donahue will continue to lead under a three-year agreement.

INVO Fertility (NASDAQ: IVF) announced a private placement priced at-the-market under Nasdaq rules to a single institutional investor on Dec 2, 2025. The company agreed to sell 2,366,864 shares (or pre-funded warrants) plus warrants to purchase up to 4,733,728 shares at a combined effective price of $1.69 per share plus accompanying warrants. Gross proceeds are estimated at approximately $4.0 million before placement agent fees and expenses. Warrants carry a $1.69 exercise price, will be exercisable upon shareholder approval, and expire five years after such approval. Closing is expected on or about Dec 3, 2025, subject to customary conditions; Maxim Group is sole placement agent. The company will file a resale registration statement with the SEC.

INVO Fertility (Nasdaq: IVF) announced on November 28, 2025 its intent to acquire Family Beginnings, a fertility clinic based in Indianapolis that serves patients across Indiana and the Midwest. This would be INVO's second acquisition after Wisconsin Fertility Institute in 2023 and aligns with its strategy to build a nationwide clinic network.

Family Beginnings offers IVF, INVOcell (IVC), IUI, third-party reproduction, fertility preservation, diagnostic testing, and patient support. Management said a term sheet was executed "over a month ago," and the deal remains subject to customary due diligence, definitive purchase agreements, closing conditions, and any required regulatory approvals.

INVO Fertility (NASDAQ: IVF) announced a 1-for-8 reverse stock split effective at 12:01 a.m. ET on November 28, 2025. Commencing with the market open on November 28, 2025, the common stock will trade on a post-split basis under the same symbol IVF.

As a result of the reverse split every eight shares will be exchanged for one share, fractional shares will be rounded up to the next whole share, and the company will have approximately 1,891,151 shares issued and outstanding after the split. The CUSIP will change to 44984F807, and authorized common shares will be adjusted to 6,250,000 after the effective time.

INVO Fertility (Nasdaq: IVF) reported Q3 2025 results on November 17, 2025, showing continued top-line growth but ongoing losses. Revenue was $1.757M, up 23% YoY; consolidated clinic revenue rose 21% YoY to $1.722M, and revenue from all clinics was $1.995M, up 18% YoY. The company reported a net loss of $2.6M versus a $1.6M loss a year earlier, and Adjusted EBITDA of $(947,568), roughly flat year-over-year.

Operational highlights include 23% organic clinic growth, 130% YoY INVOcell device revenue growth, expanded telehealth and marketing initiatives, an acquisition pipeline, and efforts to improve clinic efficiencies and integrate AI scribe technology.

INVO Fertility (Nasdaq: IVF) announced on October 27, 2025 a strategic partnership with Heidi Health to deploy Heidi’s AI-powered scribe at the Wisconsin Fertility Institute (WFI) in Middleton, Wis.

The integration will work with existing EHR systems to automate clinical documentation in real time, producing notes, case histories and follow-ups. Heidi is reported to support nearly 2 million patient interactions per week, operate in 50+ countries across 200 specialties and in over 110 languages. Heidi claims the scribe automates an average of over two hours of daily administrative work and can reduce manual note-taking by up to 80%, aiming to free clinicians for patient care and reduce burnout. Patients can learn more at www.wisconsinfertility.com or call 608-824-0075.

INVO Fertility (NASDAQ: IVF), a healthcare company focused on expanding access to advanced fertility treatments, has announced its participation in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.

The company will deliver a webcast presentation at 5:00 p.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.

INVO Fertility (NASDAQ:IVF) reported its Q2 2025 financial results, achieving record quarterly revenue of $1.86 million, up 1% year-over-year. The company's consolidated clinic revenue from Atlanta and Madison locations increased 1% to $1.83 million, while total revenue including equity method clinics rose 2% to $2.19 million.

Key operational highlights include Wisconsin Fertility Institute's recognition on Newsweek's Best Fertility Clinics list, launch of telehealth capabilities, and addition of Platelet-Rich Plasma therapy services. The company received a patent allowance for its modified INVOcell device, extending protection through 2040. INVO completed the divestiture of NAYA Therapeutics, retaining a minority stake while refocusing on core fertility operations.

However, the company reported a net loss from continuing operations of $(3.2) million, compared to $(2.2) million in Q2 2024, with Adjusted EBITDA at $(587,230).

INVO Fertility (NASDAQ: IVF) has announced a 1-for-3 reverse stock split effective July 21, 2025, at 12:01 a.m. Eastern Time. The company's common stock will continue trading under the symbol "IVF" on the Nasdaq Capital Market with a new CUSIP number 44984F708.

Following the split, every 3 shares will be consolidated into 1 share, with fractional shares rounded up. The company's outstanding shares will decrease to approximately 928,272, and authorized shares will be adjusted to 1,388,888. The primary goal is to meet Nasdaq's minimum bid price requirement of $1.00 per share for continued listing, though compliance is not guaranteed.